2782-3784

Real-World Data & Evidence

Publishing House OKI

View prefix report (10.37489)

Health Score

0 Excellent

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Deposit reference lists for 10 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact10 DOIs
2

Attach ORCID iDs across 4 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Low impact4 DOIs
3

Add abstracts to 1 article

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact1 DOIs

DOIs for this ISSN

Showing the top 5 of 103 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Resolution based on the results of the III annual scientific… (10.37489/2782-3784-myrwd-20)
References ORCID
34.95 4
2 Resolution based on the results of the IV annual scientific-… (10.37489/2782-3784-myrwd-41)
References ORCID
30.10 3
3 Considerations for the design and conduct of externally cont… (10.37489/2782-3784-myrwd-45)
References
27.85 12
4 Resolution based on the results of the conference: "RWD/ RWE… (10.37489/2782-3784-myrwd-5)
References
23.86 8
5 Review of the textbook “Clinical and pharmacological charact… (10.37489/2782-3784-myrwd-51)
References ORCID
15.05 1
6 Resolution of the VI Annual International Scientific and Pra… (10.37489/2782-3784-myrwd-083)
References
11.93 2
7 Why do we need "Real-World Data & Evidence", the new sc… (10.37489/2782-3784-myrwd-1)
References
11.93 2
8 Resolution based on the results of the V annual scientific-p… (10.37489/2782-3784-myrwd-57)
References
11.93 2
9 Review of methods for assessing the cost-effectiveness of me… (10.37489/2782-3784-myrwd-057)
0.00 0
10 Approaches to resolve practical challenges in the context of… (10.37489/2782-3784-myrwd-058)
0.00 0
11 Prerequisites and limitations of the use of oral anticoagul… (10.37489/2782-3784-myrwd-059)
0.00 0
12 Particular qualities of evaluation of electronic card data i… (10.37489/2782-3784-myrwd-060)
0.00 0
13 Assessment of quality of presentation of clinical trial resu… (10.37489/2782-3784-myrwd-061)
0.00 0
14 Educational pharmacoepidemiology and "Real-World Knowledge" (10.37489/2782-3784-myrwd-062)
0.00 6
15 Review of the monograph by Kolbin A. S., Zyryanov S. K., Bel… (10.37489/2782-3784-myrwd-063)
References ORCID
0.00 0
16 Review of real-world studies on capmatinib use in MET-mutate… (10.37489/2782-3784-myrwd-064)
0.00 0
17 Possibilities of pharmacological thromboprophylaxis in micro… (10.37489/2782-3784-myrwd-065)
0.00 0
18 Aspects of pharmaceutical care for patients with cephalgia i… (10.37489/2782-3784-myrwd-066)
0.00 0
19 Insufficient use of statins in the primary and secondary pre… (10.37489/2782-3784-myrwd-067)
0.00 1
20 Pharmacoepidemiology of antidepressants in the Russian Feder… (10.37489/2782-3784-myrwd-068)
0.00 3
21 Metadata in medicine (10.37489/2782-3784-myrwd-069)
0.00 0
22 Social significance of rheumatic diseases, negative conseque… (10.37489/2782-3784-myrwd-070)
0.00 2
23 Surrogate endpoints in cost-effectiveness analysis for use i… (10.37489/2782-3784-myrwd-071)
0.00 1
24 Evidence synthesis in neuromyelitis optica spectrum disorder… (10.37489/2782-3784-myrwd-072)
0.00 1
25 A systematic review with meta-analysis and indirect comparis… (10.37489/2782-3784-myrwd-073)
0.00 0
26 Implementation of microbiological monitoring for predicting… (10.37489/2782-3784-myrwd-074)
0.00 1
27 Methicillin-resistant staphylococci biofilms and the possibi… (10.37489/2782-3784-myrwd-075)
0.00 0
28 The ICEDORA study: clinical and demographic characteristics… (10.37489/2782-3784-myrwd-076)
0.00 0
29 Resolution of the XII All-Russian Conference with Internatio… (10.37489/2782-3784-myrwd-077)
References
0.00 0
30 Overcoming the "valley of death" in medical research and dev… (10.37489/2782-3784-myrwd-078)
0.00 0
31 Development of risk management processes for the quality of… (10.37489/2782-3784-myrwd-079)
0.00 0
32 Prospects for the application of individualized integrated a… (10.37489/2782-3784-myrwd-080)
0.00 0
33 Pharmacodynamic approach to assessing leukopenia as a marker… (10.37489/2782-3784-myrwd-081)
0.00 0
34 Impact of third molars on quality of life in modern society (10.37489/2782-3784-myrwd-082)
0.00 0
35 Medicine’s benefits and values: basic terms and modern conce… (10.37489/2782-3784-myrwd-084)
0.00 0
36 An open, observational, non-interventional, multicenter stud… (10.37489/2782-3784-myrwd-085)
0.00 0
37 The safety of the use of anti psychotics: analysis of sponta… (10.37489/2782-3784-myrwd-086)
0.00 0
38 Safety profile evaluation of direct oral anticoagulants in s… (10.37489/2782-3784-myrwd-087)
0.00 0
39 Analgesics in modern dental practice: the evolution of pain… (10.37489/2782-3784-myrwd-088)
0.00 0
40 A systematic review and meta-analysis of the efficacy and sa… (10.37489/2782-3784-myrwd-089)
0.00 0
41 The concept of an ideal real-world evidence study: industry… (10.37489/2782-3784-myrwd-090)
0.00 0
42 Medical decision support model for diagnosing and rehabilita… (10.37489/2782-3784-myrwd-091)
0.00 1
43 Safety of glucagon-like peptide-1 agonists: data from the Ru… (10.37489/2782-3784-myrwd-092)
0.00 0
44 Assessment of the effectiveness and safety of nonsteroidal a… (10.37489/2782-3784-myrwd-093)
0.00 0
45 Analysis of patients with iatrogenic hypopituitarism after c… (10.37489/2782-3784-myrwd-094)
0.00 0
46 Review of regulatory documents governing the development and… (10.37489/2782-3784-myrwd-095)
0.00 1
47 Comparative efficacy and safety of intravenous ibuprofen and… (10.37489/2782-3784-myrwd-096)
0.00 0
48 The place of real-world evidence in conducting clinical and… (10.37489/2782-3784-myrwd-097)
0.00 0
49 Clinical and demographic characteristics and treatment patte… (10.37489/2782-3784-myrwd-098)
0.00 0
50 Power BI as an auxiliary tool for biostatistics (10.37489/2782-3784-myrwd-10)
0.00 2